A guide to GMC investigations and fitness to practise proceedings
As a doctor, any complaint or concern which is raised by the General Medical Council can be confusing and stressful, particularly because the outcome may have an impact on your ability to earn a living. It is therefore crucial that you take specialist legal advice at an early stage in order to put you in the best possible position to respond to the allegation and to help you to navigate your way through the various stages of the disciplinary process.
Charles Russell Speechlys specialise in providing a full range of legal services to the healthcare sector. We have been representing healthcare professionals for over 50 years.
We have a dedicated team of solicitors who specialise in advising and representing people who are subject to fitness to practise proceedings. Our particular expertise in this area means that we are not only able to assist in relation to proceedings brought by the GMC, but we are also able to advise regarding associated issues which may be ongoing at the same time, such as investigations by the CQC; helping to protect your practice as well as you.
This guide is intended as an overview of the GMC’s fitness to practise process, and we hope that it will be of use to any medical professional concerned about fitness to practise proceedings, or who wants to know more about how the GMC regulates. It deals with the most common questions that our clients ask us when they are facing an investigation. The figures in this guide are taken from the GMC’s Annual Report 2015 (the most recent available at the time of writing) and the GMC’s website.
News & Insights
Are the days of botched pharmacy fraud investigations finally over?
David Reissner has reservations about a new drive to uncover community pharmacy contractor fraud...
Pharmacy Brief - October 2018
Welcome to the October edition of our Pharmacy Brief.
Charles Russell Speechlys advises Kreos and SVB on £20m growth capital investment to Mereo BioPharma
We advised Kreos Capital and Silicon Valley Bank on the refinancing of £20 million growth capital investment to Mereo BioPharma Group